{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:00:35Z","timestamp":1787169635814,"version":"build-2736575974"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"National Cancer Research and Development Fund","award":["2023-A-16"],"award-info":[{"award-number":["2023-A-16"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Letermovir, a moderate inhibitor of CYP3A4 and inducer of CYP2C9 and CYP2C19, is used for cytomegalovirus prophylaxis following allogeneic hematopoietic stem cell transplantation (HCT). Posaconazole also inhibits CYP3A4, affecting tacrolimus metabolism. This study aimed to examine tacrolimus conversion ratios when switching from continuous intravenous to oral administration in HCT patients receiving posaconazole with and without letermovir. Tacrolimus concentration-to-dose (C\/D) ratios before (C\/Dciv) and after (C\/Dpo) conversion were compared. The median C\/Dciv ratios were 20.1 and 22.5 (ng\/mL)\/(mg\/day) for patients with and without letermovir, respectively (P\u00a0=\u00a00.31). The median C\/Dpo ratios were 5.1 and 5.9 (ng\/mL)\/(mg\/day), respectively (P\u00a0=\u00a00.43). The median (C\/Dpo)\/(C\/Dciv) ratios were 0.25 and 0.24, respectively (P\u00a0=\u00a00.77), indicating no significant difference in tacrolimus conversion ratios with and without letermovir. Based on these findings, the tacrolimus conversion ratio in patients receiving posaconazole was estimated to be approximately 1:2, regardless of concomitant letermovir use.<\/jats:p>","DOI":"10.1093\/jjco\/hyaf101","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T07:42:53Z","timestamp":1748504573000},"page":"1189-1193","source":"Crossref","is-referenced-by-count":1,"title":["The optimal conversion ratio of tacrolimus switching from intravenous to oral tacrolimus administration in hematopoietic cell transplantation patients receiving posaconazole prophylaxis with and without letermovir"],"prefix":"10.1093","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6048-2502","authenticated-orcid":false,"given":"Toshihisa","family":"Nakashima","sequence":"first","affiliation":[{"name":"Department of Pharmacy, National Cancer Center Hospital , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azusa","family":"Kawasaki","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, National Cancer Center Hospital , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Inamoto","sequence":"additional","affiliation":[{"name":"Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumu","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironobu","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, National Cancer Center Hospital , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,10]]},"reference":[{"key":"2025100708163719900_ref1","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1086\/651263","article-title":"Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: Overview of the transplant-associated infection surveillance network (TRANSNET) database","volume":"50","author":"Kontoyiannis","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2025100708163719900_ref2","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1586\/eri.11.13","article-title":"Invasive aspergillosis in hematopoietic stem cell and solid organ transplantation","volume":"9","author":"Salman","year":"2011","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2025100708163719900_ref3","doi-asserted-by":"publisher","first-page":"100414","DOI":"10.1016\/j.dmpk.2021.100414","article-title":"Classification of drugs for evaluating drug interaction in drug development and clinical management","volume":"41","author":"Maeda","year":"2021","journal-title":"Drug Metab Pharmacokinet"},{"key":"2025100708163719900_ref4","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1177\/10781552211029046","article-title":"Comparative effects of fluconazole, posaconazole, and isavuconazole upon tacrolimus and cyclosporine serum concentrations","volume":"28","author":"Gu","year":"2022","journal-title":"J Oncol Pharm Pract"},{"key":"2025100708163719900_ref5","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s40265-017-0860-8","article-title":"Letermovir: First global approval","volume":"78","author":"Kim","year":"2018","journal-title":"Drugs"},{"key":"2025100708163719900_ref6","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/cpt.1120","article-title":"PBPK Modeling strategy for predicting complex drug interactions of Letermovir as a perpetrator in support of product Labeling","volume":"105","author":"Wang","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"2025100708163719900_ref7","doi-asserted-by":"publisher","first-page":"859","DOI":"10.7150\/ijms.42011","article-title":"Tacrolimus concentration after Letermovir initiation in hematopoietic stem cell transplantation recipients receiving Voriconazole: A retrospective","volume":"17","author":"Hikasa","year":"2020","journal-title":"Observational Study Int J Med Sci"},{"key":"2025100708163719900_ref8","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s12185-021-03277-6","article-title":"Differences in kinetics of tacrolimus concentration after letermovir discontinuation by type of concomitant azole antifungal","volume":"115","author":"Nakashima","year":"2022","journal-title":"Int J Hematol"},{"key":"2025100708163719900_ref9","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1007\/s12185-025-03942-0","article-title":"Concomitant letermovir affects the optimal concentration-to-dose ratio of tacrolimus after switching from intravenous to oral tacrolimus administration in hematopoietic cell transplantation patients receiving fluconazole prophylaxis","volume":"121","author":"Nakashima","year":"2025","journal-title":"Int J Hematol"},{"key":"2025100708163719900_ref10","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1007\/s12185-021-03105-x","article-title":"Drug interaction between letermovir and voriconazole after allogeneic hematopoietic cell transplantation","volume":"113","author":"Nakashima","year":"2021","journal-title":"Int J Hematol"},{"key":"2025100708163719900_ref11","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1097\/FTD.0000000000001198","article-title":"Population pharmacokinetic Modeling of Posaconazole in Japanese patients receiving fungal prophylaxis","volume":"46","author":"Sugimoto","year":"2024","journal-title":"Ther Drug Monit"},{"key":"2025100708163719900_ref12","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1097\/FTD.0000000000001196","article-title":"Factors influencing serum Posaconazole concentrations in patients with hematologic malignancies receiving delayed-release tablets","volume":"46","author":"Yamada","year":"2024","journal-title":"Ther Drug Monit"},{"key":"2025100708163719900_ref13","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1124\/dmd.32.2.267","article-title":"Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil)","volume":"32","author":"Ghosal","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"2025100708163719900_ref14","doi-asserted-by":"publisher","first-page":"3543","DOI":"10.1128\/AAC.48.9.3543-3551.2004","article-title":"Disposition of posaconazole following single-dose oral administration in healthy subjects","volume":"48","author":"Krieter","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"2025100708163719900_ref15","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s12185-016-2135-7","article-title":"Analysis of the variable factors influencing tacrolimus blood concentration during the switch from continuous intravenous infusion to oral administration after allogeneic hematopoietic stem cell transplantation","volume":"105","author":"Suetsugu","year":"2017","journal-title":"Int J Hematol"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/55\/10\/1189\/63465025\/hyaf101.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/55\/10\/1189\/63465025\/hyaf101.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T12:16:41Z","timestamp":1759839401000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/55\/10\/1189\/8160033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,10]]},"references-count":15,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,6,10]]},"published-print":{"date-parts":[[2025,10,7]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyaf101","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,6,10]]}}}